Howe & Rusling’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Howe & Rusling’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9	Closed	-$2K	–	1026
2016 Q3	$2K	Hold	9	–	–	﹤0.01%	836
2016 Q2	$3K	Hold	9	–	–	﹤0.01%	728
2016 Q1	$3K	Sell	9 -12	-57%	-$4.17K	﹤0.01%	760
2015 Q4	$5K	Hold	21	–	–	﹤0.01%	615
2015 Q3	$6K	Hold	21	–	–	﹤0.01%	595
2015 Q2	$5K	Buy	+21	New	+$5.21K	﹤0.01%	629

Other funds holding BIS

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Howe & Rusling's BIS Position: Q4 2016 in Review

Howe & Rusling sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2016, closing a stake of 9 shares — an estimated $2K sold.

Howe & Rusling first reported a position in BIS in Q2 2015 and held it in 6 quarters. The position peaked at $6K in Q3 2015. 13 funds tracked by Wall St. Rank hold BIS as of Q4 2016.

Howe & Rusling reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
Howe & Rusling sold 9 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2016, an estimated $2K.
Howe & Rusling first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2015 and held it in 6 quarters.
Howe & Rusling's ProShares UltraShort NASDAQ Biotechnology position peaked at $6K in Q3 2015.
13 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2016.

Based on Howe & Rusling's 13F filing for Q4 2016, filed 20 Jan 2017.